Diabetes and Heart Disease
Cardiovascular disease is the leading cause of death among people with type 2 diabetes — not kidney disease, not neuropathy, not retinopathy, but heart disease. The relationship between diabetes and heart disease is so consistent, so well-documented, and so mechanistically understood that it has reshaped how cardiologists and endocrinologists approach both conditions. Managing diabetes is now understood to be, in significant part, a cardiovascular disease prevention strategy.
Approximately 34 million Americans have diabetes, and more than 88 million have prediabetes — most without knowing it. The cardiovascular risk associated with even the prediabetic state is elevated above normal, and the risk continues to escalate with duration of diabetes and quality of blood sugar control. Understanding the mechanisms linking these two conditions, the magnitude of risk they create together, and the treatment strategies that address both simultaneously is among the most clinically important knowledge in preventive medicine today.
How Diabetes Damages the Cardiovascular System
The link between elevated blood glucose and cardiovascular damage is not a single pathway but a convergence of multiple simultaneous mechanisms — each of which would independently accelerate atherosclerosis and increase cardiovascular risk, and which together produce a far more dangerous environment than any single mechanism alone.
Advanced glycation end-products (AGEs). When blood glucose is chronically elevated, glucose molecules attach to proteins throughout the body in a process called glycation. The resulting advanced glycation end-products (AGEs) accumulate in blood vessel walls, cross-link with structural proteins like collagen, causing arterial stiffness and impaired vasodilation. AGEs also activate specific receptors (RAGE — receptor for advanced glycation end-products) on endothelial cells and macrophages, triggering oxidative stress and inflammatory cascades that damage the arterial wall and accelerate atherosclerotic plaque formation.
Endothelial dysfunction. Chronically elevated blood glucose directly impairs endothelial nitric oxide synthase — the enzyme responsible for producing nitric oxide, the primary vasodilatory molecule in the arterial system. The result is reduced vasodilation, increased vascular tone, elevated blood pressure, and an endothelial surface that becomes more adhesive to inflammatory cells and more permeable to LDL particles. The upregulation of adhesion molecules (VCAM-1, ICAM-1) promotes monocyte adhesion to the endothelium and their subsequent transformation into foam cells — the cellular foundation of atherosclerotic plaque.
Diabetic dyslipidemia. Insulin resistance — the metabolic abnormality underlying type 2 diabetes — causes the liver to overproduce very low-density lipoprotein (VLDL), raising triglycerides. It simultaneously reduces HDL cholesterol and shifts the LDL particle population toward small, dense LDL — the most atherogenic lipoprotein subtype, which penetrates the endothelium more easily and is more susceptible to oxidation. This “diabetic dyslipidemia triad” of high triglycerides, low HDL, and small dense LDL is present in prediabetes and metabolic syndrome, years before frank T2DM is diagnosed.
Pro-thrombotic state. Diabetes creates a blood environment that is simultaneously more prone to forming clots and less able to dissolve them. Elevated PAI-1 (plasminogen activator inhibitor-1) impairs fibrinolysis — the normal mechanism for breaking down clots. Platelet hyperreactivity increases the tendency for platelet aggregation at sites of vascular injury or plaque rupture. Elevated fibrinogen raises the background clotting tendency. Together, these changes mean that when an atherosclerotic plaque ruptures in a person with diabetes, the resulting thrombus is more likely to be large, more likely to completely occlude the artery, and more difficult to dissolve — producing a larger, more severe MI.
Diabetic cardiomyopathy. Distinct from the cardiovascular effects of atherosclerosis, diabetes can cause direct damage to the heart muscle itself — a condition called diabetic cardiomyopathy. This occurs through myocardial fibrosis (replacement of normal heart muscle with stiff scar tissue), impaired calcium handling in cardiomyocytes, and mitochondrial dysfunction that reduces the heart’s energy efficiency. The earliest manifestation is diastolic dysfunction — difficulty with the heart’s relaxation phase — which can progress to heart failure with preserved ejection fraction (HFpEF), the most common form of heart failure in people with diabetes. Diabetic cardiomyopathy explains why heart failure is substantially more common in diabetic patients even when coronary artery disease is absent or well-controlled.
Cardiac autonomic neuropathy. Diabetes damages the autonomic nerves that regulate heart rate, blood pressure, and cardiac rhythm. Cardiac autonomic neuropathy produces resting tachycardia, orthostatic hypotension, reduced heart rate variability, and — most dangerously — silent ischemia: the loss of normal pain signals from ischemic heart muscle. A person with diabetic autonomic neuropathy may experience a myocardial infarction without the characteristic chest pain that normally prompts emergency care, presenting instead with vague symptoms (fatigue, dyspnea, nausea) that can easily be misattributed to other causes. This silent MI phenomenon partially explains why cardiovascular events in diabetic patients are more likely to be fatal — they are often diagnosed later or not at all.
How Much Does Diabetes Raise Cardiovascular Risk?
Type 2 diabetes raises cardiovascular mortality by approximately 2 to 4 times compared to non-diabetic adults of the same age, sex, and other risk factor profile. For type 1 diabetes — which begins in childhood or young adulthood and produces decades of hyperglycemia exposure — the cardiovascular risk elevation is even more pronounced, with some studies showing 10-fold or greater increases in cardiovascular event rates.
An older concept in cardiology categorized type 2 diabetes as a “coronary artery disease risk equivalent” — meaning that a person with diabetes who had never had a heart attack was estimated to have the same cardiovascular event risk as a non-diabetic person who had already had one. This concept reflected genuine epidemiological findings but has been refined by subsequent analysis: cardiovascular risk within diabetes varies substantially based on diabetes duration, glycemic control, presence of end-organ damage (nephropathy, retinopathy, neuropathy), and coexisting risk factors. People with newly diagnosed, well-controlled type 2 diabetes without organ damage have meaningfully lower cardiovascular risk than those with 15-year duration diabetes complicated by chronic kidney disease and poor glucose control.
Notably, women with diabetes lose their pre-menopausal cardiovascular protective advantage. In the general population, women develop coronary artery disease approximately 7 to 10 years later than men — a difference attributed largely to the cardioprotective effects of estrogen. Diabetes essentially eliminates this advantage, bringing women with diabetes to cardiovascular risk levels comparable to age-matched diabetic men. This makes cardiovascular risk in women with diabetes particularly important to recognize and aggressively manage.
Prediabetes — defined as HbA1c of 5.7 to 6.4 percent or fasting glucose of 100 to 125 mg/dL — is also associated with elevated cardiovascular risk above normal, primarily through the metabolic syndrome pathways of insulin resistance, dyslipidemia, and low-grade inflammation that often accompany the prediabetic state. The cardiovascular damage from metabolic dysfunction begins before HbA1c reaches the diabetic threshold.
Medications That Protect Both the Heart and Blood Sugar
One of the most significant developments in both cardiology and endocrinology over the past decade has been the discovery that certain antidiabetic medications provide direct cardiovascular protection independent of their glucose-lowering effects — fundamentally changing treatment guidelines for people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk.
SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) — including empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana) — work by blocking glucose reabsorption in the kidney, causing glucose to be excreted in the urine and lowering blood sugar. The landmark EMPA-REG OUTCOME trial demonstrated that empagliflozin reduced cardiovascular death by 38 percent and heart failure hospitalizations by 35 percent in people with type 2 diabetes and established cardiovascular disease — results that exceeded what glucose lowering alone could explain. Subsequent trials confirmed similar benefits for dapagliflozin and canagliflozin. The cardiovascular mechanisms of SGLT2 inhibitors include osmotic diuresis (reducing cardiac preload and afterload), direct renal tubular protection that reduces cardiorenal syndrome, and potentially direct cardiac metabolic effects that improve heart muscle energy efficiency.
GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists) — including semaglutide (Ozempic/Wegovy), liraglutide (Victoza/Saxenda), and dulaglutide (Trulicity) — mimic the incretin hormone GLP-1 to increase insulin secretion, suppress glucagon, reduce appetite, and slow gastric emptying. The LEADER trial demonstrated that liraglutide reduced major adverse cardiovascular events (MACE — the composite of cardiovascular death, MI, and stroke) by 13 percent. The SUSTAIN-6 trial showed semaglutide reduced MACE by 26 percent. Beyond glycemia and cardiovascular events, GLP-1 receptor agonists produce substantial weight loss — 5 to 15 percent of body weight with injectable semaglutide — addressing obesity’s contributions to cardiovascular risk through an additional pathway.
The 2019 ACC/AHA Primary Prevention Guidelines and the American Diabetes Association Standards of Care now recommend SGLT2 inhibitors and GLP-1 receptor agonists as preferred second-line agents (after metformin) in people with type 2 diabetes who have established cardiovascular disease or who are at high cardiovascular risk, specifically because of their demonstrated cardiovascular mortality benefits. This represents a paradigm shift: the choice of antidiabetic medication is now explicitly a cardiovascular decision, not just a glycemic one.
Cardiovascular Risk Factor Targets for People with Diabetes
Managing diabetes for cardiovascular protection requires addressing multiple risk factors simultaneously, each with specific targets that may differ from recommendations for the general population.
Blood pressure is particularly important in diabetic patients, where hypertension compounds the endothelial damage from hyperglycemia in an additive or synergistic way. The ACC/AHA 2017 guidelines recommend a blood pressure target of below 130/80 mmHg in people with diabetes — the same threshold as other high-risk patients. ACE inhibitors and ARBs are preferred antihypertensive agents in diabetic patients, as they provide additional protection against diabetic nephropathy beyond blood pressure lowering.
LDL cholesterol targets are aggressive for diabetic patients. The 2018 ACC/AHA Cholesterol Guidelines recommend statin therapy for virtually all adults with type 2 diabetes aged 40 to 75, regardless of baseline LDL level, given the elevated cardiovascular risk. The LDL target for diabetic patients with established cardiovascular disease is below 70 mg/dL; for those with multiple additional risk factors, below 55 mg/dL may be appropriate with the addition of ezetimibe or PCSK9 inhibitor therapy.
Blood glucose targets are individualized. The ADA recommends an HbA1c target below 7 percent for most non-pregnant adults with type 2 diabetes. Less stringent targets (7.5 to 8 percent) are appropriate for older patients, those with limited life expectancy, or those at high risk of hypoglycemia. The ACCORD trial demonstrated that aggressive glucose lowering to HbA1c below 6 percent was associated with increased mortality in high-risk cardiovascular patients — likely due to hypoglycemia episodes triggering cardiac arrhythmias and ischemia. This has reinforced the principle of individualized glycemic targets rather than a one-size-fits-all approach.
Aspirin therapy in diabetes is now more selectively recommended. Previously advocated broadly for primary prevention in diabetic patients, the ASCEND and ARRIVE trials showed that the cardiovascular benefit of aspirin in primary prevention diabetic patients is largely offset by increased bleeding risk. Current guidelines recommend aspirin for secondary prevention (established CVD) but recommend individualized shared decision-making rather than routine use for primary prevention in diabetes.
Lifestyle Strategies That Address Diabetes and Heart Disease Simultaneously
The lifestyle factors that improve glycemic control overlap substantially with those that reduce cardiovascular risk — making intensive lifestyle intervention one of the most efficient strategies available for people with both conditions.
Weight loss is the single most impactful lifestyle intervention for type 2 diabetes and cardiovascular risk simultaneously. A 5 to 10 percent reduction in body weight improves insulin sensitivity, reduces HbA1c, lowers blood pressure, reduces triglycerides, and raises HDL cholesterol. The Look AHEAD trial — the largest randomized trial of intensive lifestyle intervention in type 2 diabetes — demonstrated that intensive lifestyle intervention producing sustained weight loss substantially reduced diabetes medication needs, reduced sleep apnea, and improved quality of life, though cardiovascular event reduction was not achieved at the study’s primary endpoint (the intervention group was healthier and had lower-than-expected event rates).
Physical activity improves insulin sensitivity through GLUT4 transporter upregulation in muscle cells, reduces HbA1c by approximately 0.6 to 0.7 percent, lowers blood pressure, reduces cardiovascular mortality risk, and provides direct cardiac benefits. The ADA recommends at least 150 minutes per week of moderate-intensity aerobic activity for adults with type 2 diabetes, with the addition of resistance training at least 2 days per week for additional glycemic benefit.
Dietary pattern affects both glycemic control and cardiovascular risk through overlapping mechanisms. The Mediterranean dietary pattern has been shown to reduce HbA1c, improve lipid profiles, and reduce cardiovascular events in people with diabetes. Low-carbohydrate dietary approaches can produce rapid glycemic improvement, particularly in the short term. The DASH diet is particularly relevant for the hypertension-diabetes combination. Any dietary approach that reduces refined carbohydrates, improves vegetable and fiber intake, and achieves a caloric deficit to support weight loss addresses both conditions simultaneously.
The American Heart Association provides detailed guidance on managing diabetes for cardiovascular health. The Centers for Disease Control and Prevention maintains diabetes statistics and prevention resources. The National Heart, Lung, and Blood Institute offers cardiovascular risk education for people with diabetes.
Related reading: What Causes Heart Disease? | Major Risk Factors for Heart Disease | Modifiable vs Non-Modifiable Heart Disease Risks | Obesity and Heart Health | Heart Attack Prevention
Sources
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment. Lancet. 1998;352(9131):837-853.
- Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373(22):2117-2128.
- Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.
- Gerstein HC, et al. ACCORD Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008;358(24):2545-2559.
- American Diabetes Association. Standards of Medical Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1).
- Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596-e646.
The Cardiorenal Connection — How Diabetic Kidney Disease Amplifies Cardiovascular Risk
Among people with type 2 diabetes, the development of diabetic kidney disease (diabetic nephropathy) represents a transition into dramatically elevated cardiovascular risk territory. The relationship between the kidneys and heart in diabetes is bidirectional and mutually amplifying — a concept now formalized as the cardiorenal syndrome — making nephropathy one of the most important risk stratifiers within the diabetic population.
Diabetic nephropathy begins as microalbuminuria — the leakage of small amounts of albumin protein into the urine, detectable only with sensitive urine tests (urine albumin-to-creatinine ratio). Microalbuminuria is not merely a sign of early kidney damage; it is an independent cardiovascular risk marker reflecting generalized endothelial injury throughout the vascular system. The same endothelial dysfunction that allows protein to leak across glomerular membranes in the kidney is occurring in the coronary arteries, carotid arteries, and peripheral vasculature simultaneously. Multiple large studies have confirmed that microalbuminuria predicts cardiovascular events at least as strongly as it predicts progression to advanced kidney disease.
As diabetic nephropathy progresses to chronic kidney disease (CKD), cardiovascular risk escalates further. Each stage of CKD reduction in GFR (glomerular filtration rate) is associated with an increase in cardiovascular event rates — not just from traditional risk factor amplification, but from CKD-specific mechanisms including anemia (reduced erythropoietin), disordered mineral metabolism (elevated phosphate, PTH, and FGF-23 promoting vascular calcification), volume overload, and uremic toxin accumulation that impairs cardiac function. At end-stage renal disease requiring dialysis, cardiovascular mortality risk is 10 to 30 times higher than the general population.
The practical clinical implication is that annual urine albumin testing and creatinine measurement are essential components of cardiovascular risk monitoring in all people with diabetes. When CKD is detected, it substantially changes the treatment priority and often justifies more aggressive intervention across all cardiovascular risk factors. SGLT2 inhibitors, in addition to their glucose-lowering and cardiovascular benefits, have demonstrated specific kidney-protective effects in diabetic nephropathy — slowing GFR decline and reducing the risk of progression to end-stage kidney disease in the CREDENCE and DAPA-CKD trials, making them essential components of treatment for diabetic patients with CKD.
Heart Failure in Diabetes — A Growing Epidemic
Heart failure — the syndrome in which the heart is unable to pump blood efficiently enough to meet the body’s metabolic needs — is substantially more common in people with diabetes than in the general population, even after accounting for differences in coronary artery disease and hypertension. The excess heart failure risk from diabetes is estimated at two to five times higher than in non-diabetic adults, and heart failure hospitalizations represent one of the most costly and frequent complications of diabetes.
The mechanisms explaining this excess risk include diabetic cardiomyopathy (as described earlier), the metabolic consequences of obesity and insulin resistance on cardiac structure and function, and the fact that diabetes accelerates hypertension-related left ventricular hypertrophy and remodeling. The most prevalent form of heart failure in diabetic patients is heart failure with preserved ejection fraction (HFpEF) — where the heart’s pumping function (ejection fraction) is maintained but relaxation is impaired. HFpEF is more common than heart failure with reduced ejection fraction (HFrEF) in diabetes, is more closely tied to obesity and metabolic dysfunction, and historically has been more difficult to treat.
The emergence of SGLT2 inhibitors as heart failure therapies has been particularly significant for diabetic patients. The EMPEROR-Preserved trial demonstrated that empagliflozin reduced cardiovascular death and heart failure hospitalizations specifically in HFpEF — the first medication class to show this benefit. This makes SGLT2 inhibitors uniquely positioned to address the most common form of heart failure in diabetes, operating through cardiac mechanisms (reduced preload, improved myocardial energetics) rather than purely metabolic ones.
Preventing Diabetes to Prevent Heart Disease
The most effective approach to the intersection of diabetes and heart disease may be preventing diabetes altogether — specifically in the large population with prediabetes whose risk for both conditions is already elevated above normal.
The Diabetes Prevention Program (DPP) — a landmark randomized trial — demonstrated that intensive lifestyle intervention (7% weight loss goal, 150 minutes/week of physical activity, dietary counseling) reduced the progression from prediabetes to type 2 diabetes by 58 percent over 3 years. Metformin therapy reduced progression by 31 percent. The DPP Outcomes Study, following participants for 15 years, confirmed that lifestyle intervention participants had lower rates of microvascular complications and cardiovascular risk factors, even after the intensive intervention period ended.
These findings establish that prediabetes — already carrying its own elevated cardiovascular risk — is an addressable condition rather than an inevitable precursor to diabetes. Weight loss of even 5 to 7 percent of body weight in the prediabetic range meaningfully reduces the probability of progression to frank diabetes, with corresponding benefits for cardiovascular risk trajectories. Given that diabetes onset typically precedes clinical cardiovascular events by 5 to 15 years, preventing diabetes in the 40s and 50s may be one of the most effective strategies for preventing heart disease in the 50s and 60s.
Healthcare providers should screen adults aged 35 to 70 with overweight or obesity for prediabetes and diabetes, and should refer those with prediabetes to evidence-based prevention programs. The CDC’s National Diabetes Prevention Program provides a framework for community-based lifestyle intervention programs with demonstrated effectiveness.